dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Kiri

Sotsiaalministeerium · 20. veebruar 2020
Viit
1.4-2/549-1
Registreeritud
20. veebruar 2020
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Liisa Lents (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond)
Lahendamise tähtaeg
28. veebruar 2020

Failid

  • 📎C.L.5.2020 (HBsAg national estimates).pdf63 KB
  • 📎E-kiri.pdf197 KB

Sisu (failidest)

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.5.2020 The World Health Organization (WHO) presents its compliments to Member States and has the honour to inform them that WHO has recently updated the national estimates for Hepatitis B surface antigens (HBsAg) biomarker prevalence in children under five years of age and the overall population. Prior to releasing these estimates, WHO is requesting that they be reviewed by national authorities and encourages Member States to provide comments on the data sources and estimates and share any information to improve their accuracy. HBsAg carrier is a precondition for Hepatitis B Virus (HBV) associated with chronic conditions such as liver cancer and cirrhosis. As the impact of HBV vaccination on liver cancer and cirrhosis is difficult to measure the Secretariat based its estimates on pre- and post-vaccination data from published studies documenting HBsAg prevalence in your region and used a statistical model to generate country specific estimates. Data were extracted on demographics of sample and geographical location via a systematic review on HBsAg prevalence over the period January 1965 to October 2018. In addition, Gross Domestic Product (GDP) per capita was assigned for each country using the UN database and vaccinated cohorts were identified for each country by linking with WHO/UNICEF data on HBV vaccine introduction (HBV third dose and birth dose). Member States are invited to nominate a focal point by sending an email to [email protected] by 28 February 2020 in order to email the specific country estimates. To predict the pre- and post-vaccination HBsAg prevalence by country WHO used a statistical model presented during the Strategic Advisory Groups of Experts (SAGE) meeting of 18 to 20 October 2016. A logistical regression model with geospatial random effects was developed including geographic and GDP difference in a distance matrix as part of a correlated autoregressive function. Variables included were sex, age, bias (e.g. indigenous peoples), vaccinated cohorts and the birth dose. Bayasian statistical package WINBUGS was used while a validation on 10% of the sample was performed. More details of the statistical model are available in the Hepatitis B surface antigen prevalence dashboard http://whohbsagdashboard.com/#global-strategies. WHO hopes that these estimates provide useful information to national programmes and partner agencies when making policy decisions on Hepatitis B control strategies including HBV vaccines and other disease reduction strategies. In addition, WHO believes these estimates can be used to estimate the impact of vaccination, once the vaccine is introduced. Page 2 C.L.5.2020 In the past, all estimates have benefited greatly from the interaction with Member States. Therefore, WHO would be grateful to receive any additional data that would improve the accuracy of these estimates on the data included up to date. Any serosurvey up to December 2019 is eligible and will be screened according to the systematic review inclusion and exclusion criteria. Inputs can be sent prior to 19 March 2020 by sending an email to Ms Ximena Riveros, Department of Immunization, Vaccines and Biologicals, Family, Women’s and Children’s Health ([email protected]). The World Health Organization takes this opportunity to renew to Member States the assurance if its highest consideration. GENEVA, 19 February 2020 Saatja: <[email protected]> Saadetud: 20.02.2020 11:14 Koopia: <[email protected]> Teema: WHO: C.L.5.2020 (HBsAg estimates) Manused: C.L.5.2020 (HBsAg national estimates).pdf; C.L.5.2020 Arabic.pdf; C.L.5.2020 Chinese.pdf; C.L.5.2020 French.pdf; C.L.5.2020 Russian.pdf; C.L.5.2020 Spanish.pdf Dear Member States of the World Health Organization, Please find attached, in the six official languages, C.L.5.2020 regarding the national estimates for Hepatitis B surface antigens biomarker prevalence. Should you have questions regarding C.L.5.2020 please send an email to [email protected]. Best regards, Department of Governing Bodies World Health Organization
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel